SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to significant investor debate over its recent stock price performance and the impact of analyst price target downgrades. Community discussions are highly polarized, with bulls pointing to the company's growth and Pepsi distribution as a potential long-term winner, while bears highlight competitive pressures and recent volatility as reasons for caution.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining traction as investors speculate on a breakout following positive analyst sentiment and improved trading volume, fueling debates between bulls expecting a squeeze to double digits and skeptics who remain wary of potential downside. The community is actively tracking technical support levels and comparing the stock's performance to sector peers while weighing the impact of consistent institutional accumulation against lingering market volatility.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors closely monitor reports of White House negotiations regarding the Crypto Clarity Act and potential legislative movement in the Senate. Community sentiment remains polarized, with many retail participants expressing frustration over stagnant price action while debating whether the upcoming regulatory clarity will trigger a long-awaited breakout.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is facing heightened volatility and intense social media debate, driven by rumors of imminent Clarity Act legislative progress and institutional accumulation by firms like ARK Invest. While some investors are betting on a massive breakout to the upside as regulatory clarity nears, others remain skeptical, citing persistent downward pressure from bearish analyst revisions and ongoing concerns about the company's long-term revenue growth.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is trending due to significant volatility following a mixed second-quarter earnings report, which highlighted strong revenue growth alongside a decline in backlog that has fueled bearish skepticism. The community is actively debating the stock's future, weighing management's optimistic long-term outlook for AI infrastructure and vertical power delivery against concerns over valuation, recent insider selling, and potential competitive pressure in the high-performance power sector.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as investors weigh strong earnings and an elevated sales guidance against broader market anxiety regarding potential defense budget shifts and regulatory pressure on shareholder distributions. The community remains focused on the company's long-term backlog and the impact of evolving geopolitical demand on key defense programs.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently trending as investors focus on the commercial scale-up of ZEVASKYN, highlighted by the activation of a seventh Qualified Treatment Center in Cincinnati. While community discourse shows frustration over the slow initial patient onboarding and stock price volatility, many are holding for the long-term potential of the firm's debt-free balance sheet and the projected profitability that could arise as treatment volumes consistently climb.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is generating significant momentum as investors digest a strategic pivot toward full-stack AI infrastructure, catalyzed by a major enterprise AI contract and the divestiture of non-core assets to fund high-margin software expansion. The community is actively debating the company's transition from a legacy operator to an industrial AI platform, with bulls focusing on measurable contract deadlines and infrastructure execution while bears remain skeptical about sustainable margin quality.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is gaining traction as investors focus on the completion of Phase 3 enrollment for its lead depression treatment, HLP003, and anticipation of a topline data readout in late 2026. Community discussion is heavily centered on the company's competitive position within the psychedelic biotech sector, with frequent debates regarding the potential for acquisition by Big Pharma and the impact of evolving FDA regulatory guidance.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and trading volume as investors closely watch the company's progress on AI infrastructure contracts and the impending closure of the Alkira acquisition. The community is actively debating whether the current price reflects a deep-value turnaround opportunity or if the stock remains constrained by legacy business declines and ongoing leadership challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immuneering Corp Appoints Andrew Gengos As CFO

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16...

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

Equity

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.


Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...

Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...

Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.27	--	--	N/A
Q1 '26	-$0.25	-$0.21	16.67%	BEAT
Q4 '25	-$0.31	-$0.18	42.39%	BEAT
Q3 '25	-$0.39	-$0.38	2.15%	BEAT
Q2 '25	-$0.40	-$0.40	0.07%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMRXImmuneering Corp

Upcoming Earnings: Q2 '26

Historical Earnings

Latest IMRX News